Wall Street Business News

Quantum Materials Corp Issues Shareholder Update

March 23, 2017
  0
  • Facebook
  • Twitter
  • Google+
  • Facebook
  • Twitter
  • Google+
Latest News
  • REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
  • ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile
  • Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
  • Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
  • Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
  • Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
  • FSIS Recall 069-2019 Foreign Matter Contamination: RUIZ FOODS PRODUCTS INC. RECALLS BACON BREAKFAST WRAP PRODUCTS DUE TO POSSIBLE FOREIGN MATTER CONTAMINATION
  • SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS INVVY, PYX, TUSK INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Copyright 2018 Wall Street Business News
  • Pink Sheets
  • OTCBB

Wall Street Business News

Latest News
  • REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV
  • ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile
  • Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
  • Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting
  • Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress

Start typing and press Enter to search